Document is current

Article History

Received: 1 November 2025

Accepted: 25 May 2026

First Online: 2 June 2026

Declarations

:

: Dr. Fujisaki reported receiving honoraria from AstraZeneca, Chugai Pharmaceutical, Eli Lilly, and Kyowa Kirin, outside the submitted work. Dr. Naito reported receiving honoraria from ONO Pharmaceutical CO. Ltd and Tsumura & Co.; consulting fees from Pfizer Inc., Tensegrity Pharma, Inc., AstraZeneca K.K., Taiho Pharmaceutical Co. Ltd.; grants from Otsuka Pharmaceutical CO. Ltd., Kracie, Ltd., all outside the submitted work. Dr. Kataoka reported receiving honoraria from Chugai PHARMACEUTICAL CO., LTD, outside the submitted work. Dr. Saito reported receiving honoraria from AstraZeneca, outside the submitted work. Dr. Matsuda reported receiving honoraria from Chugai PHARMACEUTICAL CO., LTD, outside the submitted work. Dr. Kobayashi reported receiving honoraria from Eli Lilly K.K, Novartis Pharma K.K., Taiho Pharmaceutical Co.,LTD., AstraZeneca, Chugai Pharmaceutical Co.,LTD., Ono Pharmaceutical Co.,LTD., Bristol-Myers Squibb Company, and DAIICHI SANKYO COMPANY, outside the submitted work. Dr. Ko reported receiving honoraria from Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, AstraZeneca, Ono Pharmaceutical, Daiichi Sankyo, MSD, Bristol-Myers Squibb, Takeda Pharmaceutical, and Janssen Pharmaceutical; and grants from MSD, AstraZeneca, Chugai Pharmaceutical, Boehringer Ingelheim, Nuvalent, Amgen, Novocure, and Daiichi Sankyo, all outside the submitted work. Dr. Wakuda reported receiving honoraria from Chugai Pharmaceutical Co.,Ltd, Taiho Pharmaceutical, Boehringer Ingelheim, Eli Lilly K.K, Ono Pharmaceutical, MSD, Astrazeneca, Daiichi Sankyo, Janssen Pharmaceutical K.K., Takeda Pharmaceutical, Nihon Kayaku, and AMGEN; and grants from Chugai Pharmaceutical Co.,Ltd, AstraZeneca, Novartis, Abbvie, AMGEN, MSD, Daiichi Sankyo, Dizal Pharma, and Pfizer, all outside the submitted work. Dr. Ono reported receiving honoraria from Astrazeneca K.K., Bristol Myers Squibb, Chugai Pharmaceutical, Janssen Research & Development, Kyowa Kirin, MSD, Nippon Kayaku, Ono Pharmaceuticals, and Taiho Pharmaceuticals, outside the submitted work. Dr. Murakami reported receiving honoraria from Chugai Pharmaceutical, Taiho Pharmaceutical, AstraZeneca, Eli Lilly Japan, Ono Pharmaceutical, Bristol Myers Squibb, MSD, Takeda Pharmaceutical, Novartis, Daiichi Sankyo, and Amgen; consulting fees from Chugai Pharmaceutical, GAIA BioMedicine, and Daiichi Sankyo; and research funding from AstraZeneca, AbbVie, Daiichi Sankyo, Chugai Pharmaceutical, Bayer, Eli Lilly, Taiho Pharmaceutical, and Pfizer, all outside the submitted work. Dr. Takahashi reported receiving honoraria from AstraZeneca KK, Chugai PHARMACEUTICAL CO., LTD, MSD K.K., Janssen Pharmaceutical K.K., Eli Lilly Japan K.K., Pfizer Japan Inc., DAIICHI SANKYO CO., LTD, Amgen K.K., BMS Japan., TAIHO PHARMACEUTICAL CO., LTD, Takeda PHARMACEUTICAL CO LTD., ONO PHARMACEUTICAL CO., LTD., and Takeda PHARMACEUTICAL CO LTD.; and grants from AstraZeneca KK, MSD K.K., Janssen Pharmaceutical K.K., Amgen K.K., and AnHeart Therapeutics Inc., all outside the submitted work. Dr. Kenmotsu reported receiving honoraria from Amgen inc., AstraZeneca K.K., Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical Co, Ltd., Daiichi-Sankyo Co., Ltd., Eli Lilly K.K, Kyowa Hakko Kirin Co., Ltd., Merck, MSD, Novartis Pharma K.K., Ono Pharmaceutical Co, Ltd., Pfizer, Taiho Pharma, Takeda Pharmaceutical Co., Ltd, Janssen Pharmaceutical K.K., Thermo Fisher Scientific Inc., and Guardant; and grants from Ono Pharmaceutical Co, Ltd., Novartis Pharma K.K., Eli Lilly K.K, AstraZeneca K.K., and Loxo Oncology, all outside the submitted work. No other disclosures were reported.